Get the Stockscreener App
0.8019
3.39%
-0.0281
After Hours:
.76
-0.0419
-5.23%
Indaptus Therapeutics Inc stock is traded at $0.8019, with a volume of 15,991.
It is down -3.39% in the last 24 hours and down -15.59% over the past month.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
See More
Previous Close:
$0.83
Open:
$0.8051
24h Volume:
15,991
Relative Volume:
0.60
Market Cap:
$9.63M
Revenue:
-
Net Income/Loss:
$-15.42M
P/E Ratio:
-0.4358
EPS:
-1.84
Net Cash Flow:
$-13.41M
1W Performance:
-14.24%
1M Performance:
-15.59%
6M Performance:
-52.83%
1Y Performance:
-54.18%
1-Day Range:
$0.80
$0.8339
1-Week Range:
$0.80
$0.98
52-Week Range:
$0.80
$3.10
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
0.8019 | 9.63M | 0 | -15.42M | -13.41M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
Indaptus Therapeutics expands cancer trial to Canada - Investing.com India
Indaptus Therapeutics Files Prospectus Relating To Proposed Resale By Selling Stockholders Of Up To 4.4 Million Shares - Marketscreener.com
Indaptus Therapeutics expands cancer trial to Canada By Investing.com - Investing.com South Africa
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 - The Manila Times
Major Clinical Trial Expansion: Indaptus' Cancer Immunotherapy Decoy20 Gets Canadian Green Light - StockTitan
Head-To-Head Contrast: Indaptus Therapeutics (NASDAQ:INDP) vs. Biofrontera (NASDAQ:BFRI) - Defense World
Indaptus Therapeutics Receives Notification from Nasdaq Regarding Minimum Bid Price RequirementUnited States Securities and Exchange Commission, Washington, DC 20549Form 8-KIndaptus Therapeutics, Inc. recently received a notification from Nasda - Defense World
Indaptus Therapeutics looks to raise $2.25M in private placement - MSN
Indaptus Therapeutics Announces $2.25 Million Private Placement - Defense World
Indaptus Therapeutics, Inc. announced that it expects to receive $2.246493 million in funding - Marketscreener.com
Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times
Indaptus Therapeutics Secures $2.25M Private Placement for R&D Advancement - StockTitan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 - The Manila Times
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 - GlobeNewswire Inc.
Indaptus Therapeutics (NASDAQ:INDP) Trading Up 6.3% – Still a Buy? - Defense World
INDP stock touches 52-week low at $0.81 amid market challenges - Investing.com Canada
Viracta stock falls on strategic review (VIRX:NASDAQ) - Seeking Alpha
Indaptus Therapeutics files to sell 1.94M shares of common stock - MSN
Indaptus Therapeutics (NASDAQ:INDP) Shares Down 1% – Here’s Why - Defense World
Gram-negative bacteria platform offers multiple immune receptor agonists for tumor immunotherapy - BioWorld Online
Indaptus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Indaptus Therapeutics announces $2.135M registered direct offering - MSN
Indaptus secures $2.1 million through stock and warrants sale By Investing.com - Investing.com Canada
Indaptus secures $2.1 million through stock and warrants sale - Investing.com India
Indaptus Therapeutics Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement - citybiz
Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement - The Manila Times
Indaptus Therapeutics Secures $2.1M Direct Offering with Insider Participation | INDP Stock News - StockTitan
Blackwell 3D to Attend The Big 5 Global Construction Show in Dubai - The Manila Times
Maxim Group Has Lowered Expectations for Indaptus Therapeutics (NASDAQ:INDP) Stock Price - Defense World
Indaptus Therapeutics Inc (INDP) Quarterly 10-Q Report - Quartz
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology - The Manila Times
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting - The Manila Times
Indaptus' Decoy20 Shows Promise: Phase 1 Trial Reports Safe Weekly Dosing in Cancer Study | INDP Stock News - StockTitan
Invention and characterization of a systemically administered, attenuated and killed bacteria-based multiple immune receptor agonist for anti-tumor immunotherapy - Frontiers
Rx Rundown: Opella, Samsung Biologics, Dimension and more - MM+M Online
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences - The Manila Times
Indaptus Therapeutics partners with BeiGene for cancer study By Investing.com - Investing.com Canada
Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment - Morningstar
Indaptus Therapeutics partners with BeiGene for cancer study - Investing.com
Indaptus Therapeutics Announces Clinical Supply Agreement - GlobeNewswire
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations - The Manila Times
Indaptus Therapeutics, Inc. Enters into Clinical Supply Agreement with Beigene Switzerland GmbH - Marketscreener.com
Provident Bank's First-Time Home Buyer Survey Reveals That While Homeownership Continues to Be Challenging, Many Americans Are Finding Their Home in Less Than a Year - The Manila Times
Indaptus Therapeutics Initiates Unrestricted Enrollment of - GlobeNewswire
Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data - Investing.com
Indaptus Therapeutics (INDP) Price Target Increased by 25.00% to 10.20 - MSN
Indaptus Therapeutics Founder and Chief Scientific Officer - GlobeNewswire
Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Increases By 140.5% - Defense World
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):